Day 1 :
Keynote Forum
Mukesh Verma
National Institutes of Health, United States
Keynote: Risk prediction of cancer by epigenetics
Time : 9:30 AM - 10:15 AM
Biography:
Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH) with expertise in implication of epigenome, microbiome, metabolome and genomic information for risk assessment and understanding disease etiology. He has received MSc from Pantnagar University and PhD from Banaras Hindu University, India. He did his Postdoctoral research at George Washington University and was a Faculty Member at Georgetown University Medical Center. He was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevention of cancer, epigenetics, epidemiology and cancers associated with infectious agents. He has published 161 research articles and reviews and edited fi ve books in cancer biomarkers, epigenetics and epidemiology field.
Abstract:
Several approaches are applied to identify risk of developing cancer in diff erent ethnic and racial groups. One of the approaches is epigenetics that facilitates cancer control throughout the cancer core continuum. To understand current progress and trends in the inclusion of epigenetics in cancer epidemiology, we evaluated the published literature and the National Cancer Institute (NCI) supported research grant awards in this fi eld to identify trends in epigenetics research. We present a summary of the epidemiological studies in NCI’s grant portfolio (from January 2005 through December 2012) and in the scientifi c literature published during the same period, irrespective of support from NCI. NCI supported RPGs related to epigenetic epidemiology funded from January 01, 2005 to December 31, 2012 were included in the portfolio analysis. Th e portfolio was analyzed using NCI’s Portfolio Management Application soft ware version 13.4. Th e criteria for inclusion of a project in the analysis were as follows: (1) Th e focus of the project is cancer, (2) study involves human subjects, (3) focus of at least one of the specifi c aims in the project is cancer epigenetics, and (4) has at least 100 cases and 100 controls. Th e initial analysis identifi ed 84 RPGs. A manual analysis applying the above criteria eliminated 21 RPGs leaving 63 for further analysis. Biomarkers identifi ed in the analysis might be useful in risk prediction of diff erent cancers. Breast cancer was the most frequently studied cancer type in grants and publications. Blood cells and tumor tissue were the most commonly used biospecimens in these studies, although buccal cells, cervical cells, sputum and stool samples also were used. DNA methylation profi ling was the focus of the majority of studies, but several studies also measured microRNA profi les. We illustrate here the current status of epidemiologic studies that are evaluating epigenetic changes in large populations. Some research needs include developing improved strategies for epigenetic data analysis and interpretation; determining the stability of epigenetic marks in repeated biospecimen samples from the same people over time and studies that examine the relationship between epigenetic marks in germline DNA and tumor DNA. While there are limitations to the broad application of epigenomics to epidemiology research, there are situations where this type of research is appropriate and it should be considered.
Keynote Forum
Jenny Wang
University of New South Wales, Australia
Keynote: Epigenetic and metabolic regulation of leukemia stem cells
Time : 11:15 AM - 12:00 PM
Biography:
Jenny Wang is the Head of the Cancer and Stem Cell Laboratory at the University of New South Wales, Sydney, Australia. She had worked in Children’s Hospital Boston, Harvard Medical School, while doing Postdoctoral Research in Leukemia Stem Cell Biology. Her researches mainly focuses on to develop novel therapeutic strategies specifi cally targeting leukemia stem cells that are often resistant to commonly used cancer therapies and that are now believed to be the engine driving the growth of a tumor and the major cause for treatment failure and relapse in leukemia.
Abstract:
Acute myeloid leukemia (AML) remains a signifi cant challenge for oncologists, with a 5-year survival rate of only 27% and a standard treatment that has not changed meaningfully in the past 3 decades. Current treatments are largely ineff ective as they do not kill quiescent leukemia stem cells (LSCs) and resistant LSCs will survive to regenerate additional leukemic cells through their self-renewal capacity. Targeting self-renewal pathways that drive LSC development is essential for curative therapy. Oncogenic events including genetic, epigenetic and metabolic abnormalities enable LSCs to hijack normal stem cell of self-renewal mechanisms that allow LSCs to evade therapy and regenerate new leukemia, leading to relapse. Targeted disruption of abnormal stem cell self-renewal represents a novel therapeutic strategy that could signifi cantly reduce the capacity of a tumor to regenerate itself aft er treatment and has become a new focus for drug development in poor prognosis AML.
Keynote Forum
Suraiya Rasheed
University of Southern California, USA
Keynote: Biomarkers of a stem cell melanoma
Time : 10:15 AM - 11:00 AM
Biography:
Suraiya Rasheed is a Professor and Director of Viral Oncology and Proteomics Laboratory in the Department of Pathology at the Keck School of Medicine, University of Southern California, Los Angeles, USA. She has graduated with honors and received her fi rst PhD from Osmania University, Hyderabad, India and second PhD from London University and FRCPath from the Royal College of Pathology, London. She has also served numerous national and international Advisory Committees including Study Sections of the National Cancer Institute, National Institute of Allergy and Infectious Diseases, Antiviral Drug Development and Drug- Screening Programs for AIDS and Abstract Reviewing Committee for the International AIDS Society’s conferences.
Abstract:
Melanomas are a group of heterogeneous tumors that arise in the epithelial cells of the skin, eye, meninges and other parts of the body. Patients with highly malignant melanomas do not respond well to the conventional therapies because most of these tumors are detected aft er they have invaded multiple tissues. For a number of years, we have studied a highly malignant cat melanoma cell line (CT1413) and examined its genome-wide proteomes at diff erent stages of tumor growth by mass spectrometry. Subtractive proteomics analyses and comparisons of protein profi les of tumor cells with normal cat embryo fi broblasts and a human leukemia cells indicated that CT1413 had a unique profi le, which did not match any other cells. Extensive bioinformatics analysis of all proteins indicated that >95% of proteins expressed in this melanoma are similar to proteins that are normally expressed during the growth and development of mammalian embryos. Proteomics analyses of several single cell clones of the cat melanoma indicated that this is a clonal tumor which is most likely derived from a single embryonic stem cell that transformed into tumor cell due to abnormal cell signaling events during the embryonic development. Each of the clones tested in multiple experiments conducted over one year period exhibited embryonic proteins. Th is phenomenon is in contrast to many human cancer stem cells that are diff erent areas of the tumor mass and exhibit only a few stem cell markers. Our bioinformatics analyses have identifi ed proteins/enzymes and transcriptional regulators that are essential for diff erentiation of diff erent tissue types/organ systems, development of neural network in the brain and proteins that regulate self-renewal and maintain stemness in these tumor cells. Th ese proteins provide unique biomarkers for the early detection of malignant melanomas and/or as targets for the development of novel therapeutic strategies for treating stem-cellderived melanomas.
Keynote Forum
Manal H Al Khanbashi
Higher College of Technology, Oman
Keynote: Insights of breast cancer epigenetics: An intersection between the endogenous and exogenous systems
Time : 12:00 PM - 12:30 PM
Biography:
Manal H Al Khanbashi is currently working as a Lecturer at Applied Science Department of Higher College of Technology, Oman. She has completed her PhD in Medicine, Breast Cancer Genetics and graduated from Sultan Qaboos University and Karolinska Institute, Sweden. She has also worked in breast cancer epigenetics where miRNA, methylation and cancer related studies were covered.
Abstract:
Epigenetics acts as a vital intersect between environmental factors being exogenous and cellular and pathological processes being endogenous. Many studies have suggested that epigenetics alterations manifest to diseases as result of environmental, microbial, UV light exposure, dietary including alcohol consumption and smoking and lifestyle factors increasing the risk of cancer. Th e reversibility fact of epigenetics eff ects serve as a fertile platform in oncological and cancer studies, of which DNA methylation, histone modifi cation, microRNA expression and many others widen the doors for biomarker search for early detection, diagnosis, classifi cation along with therapy targets and prevention. Aberrations in DNA methylation pattern and miRNA expression profi le are established in breast cancer and exhibit good example of epigenetic eff ect resulting from the exogenous and exogenous interactions. Herein, this paper will shed light on the predisposition of these exogenous epigenetic eff ects factors like diet and the potential reversibility and preventive possibilities of breast cancer as endogenous manifestation.
- Cancer Types | Cancer Diagnostics and Staging | Epigenetics | Clinical Applications of Epigenetics |Clinical Biomarkers | Predictive Cancer Biomarkers
Location: Japan
Chair
Suraiya Rasheed
University of Southern California, USA
Co-Chair
Jenny Wang
University of New South Wales, Australia
Session Introduction
Manal H. Al Khanbashi
Higher College of Technology, Oman
Title: Insights of Breast Cancer Epigenetics: An intersection between the endogenous and exogenous systems.
Biography:
Manal H Al Khanbashi is currently working as a Lecturer at Applied Science Department of Higher College of Technology, Oman. She has completed her PhD in Medicine, Breast Cancer Genetics and graduated from Sultan Qaboos University and Karolinska Institute, Sweden. She has also worked in breast cancer epigenetics where miRNA, methylation and cancer related studies were covered.
Abstract:
Epigenetics acts as a vital intersect between environmental factors being exogenous and cellular and pathological processes being endogenous. Many studies have suggested that epigenetics alterations manifest to diseases as result of environmental, microbial, UV light exposure, dietary including alcohol consumption and smoking and lifestyle factors increasing the risk of cancer. Th e reversibility fact of epigenetics eff ects serve as a fertile platform in oncological and cancer studies, of which DNA methylation, histone modifi cation, microRNA expression and many others widen the doors for biomarker search for early detection, diagnosis, classifi cation along with therapy targets and prevention. Aberrations in DNA methylation pattern and miRNA expression profi le are established in breast cancer and exhibit good example of epigenetic eff ect resulting from the exogenous and exogenous interactions. Herein, this paper will shed light on the predisposition of these exogenous epigenetic eff ects factors like diet and the potential reversibility and preventive possibilities of breast cancer as endogenous manifestation.
Pedro Sanchez Rovira
Jaen Hospital Complex, Spain
Title: A metabolomics approach for therapy response in breast cancer
Biography:
Pedro Sanchez-Rovira has completed his PhD from Sevilla University and Postdoctoral studies from Córdoba University School of Medicine. He is the Director of Oncology Unit in Jaen Hospital. He has published more than 75 papers in reputed journals and has been serving as an Editorial-Board Member of repute.
Abstract:
Due to its broad clinical heterogeneity, the treatment of breast cancer is based on a wide variety of protocols. However, only a fraction of patients will show a benefi cial response. Th e discovery of biomarkers which enable the classifi cation of responders and non-responders patients may have important implications to treatment protocols and outcomes. In this study, we carried out a metabolomic profi ling of 46 serum samples of breast cancer patients at diagnostic to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy. To this end, we analyzed the samples using liquid chromatography couple to high resolution mass spectrometry LC-HRMS and the data matrix obtained was subjected to univariate and multivariate statistical analysis.
- Cancer Epigenetics | Biomarkers and Bioinformatics Development in Epigenetics | Treatment and Therapy | Cell Free Biomarkers | Advances of Biomarker Testing | Predictive Cancer Biomarkers
Location: Japan
Chair
Atsushi Kaneda
Chiba University, Japan
Co-Chair
Safana Salim Al Saidi
Ministry Of Health, Muscat
Session Introduction
Glenn Deng
Stanford University School of Medicine, USA.
Title: Single-cell molecular analysis reveals a possibility of epithelial to circulating tumor cell transition when a tumor cell enters into the bloodstream
Biography:
Glenn Deng has completed his PhD from Tokyo University in Marine Science and Technology and Postdoctoral studies from Stanford University. He is the Professor of China Three Gorges University School of Medicine and the Senior Scientist of Stanford University School of Medicine. He has published more than 30 papers in reputed journals.
Abstract:
Circulating tumor cells are important biomarkers function as liquid biopsies for cancer diagnostics and therapeutics. However, traditional analyses of tumor cells and tissues are not suitable for circulating tumor cells due to the limited number of circulating tumor cells and the molecular analyses of a population of tumor cells that may miss crucial information such as single-cell heterogeneity. Th erefore, we have developed an automatic device that isolates live circulating tumor cells from a breast cancer patient's blood sample and performs a range of single-cell molecular analyses to determine tumor cell characteristics. Th e developed automatic device isolates live circulating tumor cells from patients' blood samples. Th is device is useful for the positive enrichment, negative enrichment or diff erent combinations of negative and positive enrichment of circulating tumor cells. Up to 100 gene expression analyses were performed on the isolated single circulating tumor cells with the profi le of the 100 genes showing great heterogeneity at the single-cell level on housekeeping genes expression and the molecular signatures of apoptosis, stem cell, transition, etc. About 1/3 of the analyzed CTCs lost housekeeping genes, suggests that these CTCs were already dead or lost the ability to continue growing. Th ere is also a large portion of CTCs that either does not express or have low levels of mesenchymal cell signatures, suggesting the current EMT hypothesis only happened in limited numbers of CTCs. Our single-cell molecular analysis results on breast cancer patients' CTCs reveals that there is a strong possibility that when an epithelial cell enters the bloodstream, its fi rst transition will be epithelial to circulating tumor cell transition (ECT), followed by the CTCs performing the circulating to mesenchymal cell transition (CMT) and fi nally the mesenchymal to epithelial cell transition (MET). Our results also suggest that the ECT transition may be very important for the survival of early CTCs in the bloodstream and may lead to more investigations about the survival ability and metastatic possibility of tumor cells at the DNA and RNA level.
Ladan Teimoori-Toolabi
Pasteur Institute of Iran, Iran
Title: Studying methylation status of p16, p14, MLH1, APC and UNC5C in the plasma as diagnostic biomarkers of colorectal cancer
Biography:
Ladan Teimoori-Toolabi has completed her MD, PhD and Postdoctoral studies from Pasteur Institute of Iran. She is an Associate Professor in Molecular Medicine Department of Pasteur Institute of Iran. She has published more than 35 papers in reputed journals in ISI and has been serving as an Editorial-Board Member of two journals.
Abstract:
Colorectal cancer, in spite of diff erent screening strategies is detected in late stages in Iranians patients. Hence, we aimed to study if diff erent epigenetic markers could be helpful in detecting colorectal cancer in any stages. We studied 50 patients (25 males and 25 females) aff ected with colorectal cancer. Plasma of patients was extracted before any surgical operations. Aft er extraction of free DNA in the plasma, the methylation status of P16, P14, MLH1, APC and UNC5C in the plasma of these patients in comparison with the plasma of normal controls was studied by High Resolution Melting Curve Analysis technique. It was shown that P14, P16 and MLH1 were not methylated in the palms of these patients. Th ree sites in CpG islands of P14, P16 and MLH1 were studied by this technique. Th ree sites of UNC5C were studied by HRM. It was shown that 15%, 32.5% and 12.5% of DNA plasma samples in patients with colorectal cancer were methylated from 12.5% to 75%. Also, three sites of APC gene were studied in these patients. In addition, three sites of APC gene were studied by HRM. In 50%, 75% and 70% of patients, APC was methylated in plasma samples. Plasma samples of normal controls was studied too and it was shown that none of the genes in the plasma samples of normal controls was methylated. Th is study shows that UNC5C and APC methylation can be considered as good candidates for diagnosis of colorectal cancer though more studies are needed before considering them as markers.
Sang Hyun Lee
Duke-NUS Medical School, Singapore
Title: Dual Blockade of the Lipid Kinase and Mitotic Pathways Leads to Ras Activated Cancer-selective Lethality
Biography:
Achieving robust cancer-specifi c lethality is the ultimate clinical goal. Here we identify a compound with dual-inhibitory properties, named a131 that selectively kills cancer cells, while protecting normal cells. Th rough an unbiased CETSA screen, a proteome-wide drug-target engagement mapping, we identify the PIP4K lipid kinases as the target of a131. Ablation of the PIP4Ks generates a phenocopy of the pharmacological eff ects of PIP4K inhibition by a131. Notably, PIP4Ks inhibition by a131 causes reversible growth arrest in normal cells by transcriptionally up-regulating PIK3IP1, a suppressor of the PI3K/Akt/ mTOR pathway via altering epigenettic regulation. Strikingly, Ras activation overrides a131-induced PIK3IP1 up-regulation and activates the PI3K/Akt/mTOR pathway. Consequently, Ras-transformed cells override a131-induced growth arrest and enter mitosis where a131’s ability to de-cluster supernumerary centrosomes in cancer cells eliminates Ras-activated cells through mitotic catastrophe. Our discovery of drugs with a dual-inhibitory mechanism provides a unique pharmacological strategy against cancer and evidence of cross-activation between the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways via a Ras|PIK3IP1|PI3K signaling network in Ras-pathway activated cancer cells and clinical samples from patients with colorectal and lung adenocarcinomas via epigenetic mechanisms.
Abstract:
Sang Hyun Lee is currently an Associate Professor in the Cancer & Stem Cell Biology Program at Duke-NUS. He is trained at Comprehensive Cancer Center, University of California-San Francisco with Professor Frank McCormick and at Keio Medical School in Tokyo with Professor Hideyuki Saya.
Jose Perez del Palacio
MEDINA Foundation, Spain
Title: Predictive biomarker discovery of treatment response in lung cancer: A metabolomic approach
Biography:
Jose Perez Del Palacio is a Scientist with 18 years of industrial experience in a leading pharmaceutical research company (Merck Sharp & Dohme), working mainly in biochemistry and drug discovery. He has broad knowledge of bioanalysis technologies and metabolomics. He has additional experience and specialization in analytical methods development for HPLC, LC/MS/MS, GC and GC/MS systems. He is the author of several papers, scientifi c posters and presentations at international conferences and congresses.
Abstract:
Although the broad range of chemotherapeutic agents approved in the late years, it is a challenge for oncologists to choose which drug or combination of drugs will represent the best option for each individual, since only a portion of patients will respond properly. In this regard a biomarker approach to predict patient response to treatment may be very helpful in the making decision process. Metabolomics, the unbiased identifi cation and quantifi cation of small molecule metabolites in biological samples, is particularly promising for biomarker development because altered metabolism is considered a hallmark of cancer. In this work, we have investigated the metabolome of 115 plasma samples from lung cancer patients by mean of liquid chromatography high resolution mass spectrometry. Th e obtained data matrix was analyzed according the clinical response to each therapy (Neoadjuvant and Inmunotherapy) in order to search for a predictive molecular signature in each group of patients.
Safana Salim Al Saidi
Ministry Of Health, Muscat
Title: Validity of prostate health index and percentage of [-2]pro-prostate-specifi c antigen as novel biomarkers in the diagnosis of prostate cancer fi rst reported Omani tertiary hospitals experience
Biography:
Safana Salim Al Saidi is a Chemical Pathologist and Specialist, working at the Directorate General of Quality Assurance Centre, Ministry of Health, Oman. She has graduated from Medical College, Sultan Qaboos University, Oman in 2003 as a Medical Doctor and completed her Residency training program in Clinical Biochemistry by Oman Medical Specialty Board (OMSB) in 2014. Presently she is a Fellow of the Royal College of Pathologist, UK. She has three publications to her credit and has great interest in conducting researches which are of help to the patients.
Abstract:
Statement of the Problem: Prostate cancer is the leading cancer in older men. When prostate cancer is detected early (organ defi ned), it is potentially curable by radical prostatectomy. As per the Ministry of Health (MOH) Oman Cancer Incidence Registry, cancer of prostate is the second most common cancer (in males) and seventh most common cancer (in both males and females), with 57 cases were diagnosed in 2011. Th erefore, early detection is important and prostate-specifi c antigen (PSA) is widely used as a laboratory test for this purpose. However, despite its wide use, its value in screening men particularly asymptomatic is controversial particularly in term of risks and benefi ts of early detection. Methods: Th is is an observational prospective study that included 136 male patients aged (mean±SD: 67±8.89; range 45-90) who were scheduled for prostate biopsy in two diff erent tertiary care teaching hospitals in Muscat, Oman. Blood specimens from these patients were collected at the same setting before obtaining the prostatic biopsy; the sera were stored at -200 °C until analysis. Laboratory measurements of the three prostate specifi c antigen (PSA) markers (tPSA, fPSA and [-2]proPSA) were processed using UniCell DxI 600 Access Immunoassay System (Beckman Coulter, USA). Calculation of Prostate Health Index (phi) using Access Hybritech phi® soft ware was performed too. Th e histopathological report of the prostatic biopsy for each patient was obtained from the histopathology laboratory of the concerned hospital along with the clinical and laboratory data through the Hospital Information System (HIS). Results: Th e study showed that Phi has the best validity markers as compared with other prostate markers. It gave sensitivity and specifi city of 82.1% and 80.6%, respectively with AUC of 0.81 at cutoff value of 41.88. Th e remaining prostate markers showed sensitivities and specifi cities of 78.6% and 25.9% for tPSA; 35.7% and 92.6% for %fPSA; 64.3% and 82.4% for %p2PSA: and 75% and 35.2% for age-adjusted tPSA, respectively. Th eir AUCs at the best cutoff values were 0.67 at 10.1 μg/L for tPSA; 0.70 at 11.6% for %fPSA; 0.55 at 1.4% for %p2PSA and 0.50 for age-adjusted tPSA. Conclusion: Th e study has proved the usefulness of Phi and its component assays in predicting the diagnosis and prognosis in men who are suspected of having prostate cancer. Th e use of Phi outperforms other conventional prostate markers; tPSA and fPSA, when used alone or in combination. Phi appears to be more accurate than tPSA and fPSA in terms of excluding prostate cancer before biopsy; hence it helps the physicians to avoid unnecessary biopsies, particularly in patients with gray zone tPSA level. Phi is the strongest marker that also correlates proportionally with Gleason Score and therefore it is also useful in predicting the aggressiveness of the disease
In-Hye Jung
University of Ulsan College of Medicine, Seoul, South Korea
Title: EGF induces paradoxical growth arresting via the up-regulation of PTEN by activating Ref-1/Egr-1 in human NSCLC cells
Biography:
In-Hye Jung has completed her MSc from University of Ulsan College of Medicine. She is the Fellow in Department of Radiation Oncology of Asan Medical Center.
Abstract:
Epidermal growth factor receptor (EGFR) signaling promotes cell proliferation and survival in several types of cancer. Here, however, we showed that EGF inhibits proliferation and promotes apoptosis in non-small cell lung cancer (NSCLC) cells. In A549 cells, EGF increased redox factor-1 (Ref-1) expression and the association of Ref-1 with zinc fi nger-containing transcriptional regulator (EGR1) via activation of p22phox, RAC1 and an NOX subunit. EGF increased p22phox and RAC1 expression through activation of purinergic receptors (P2Y). Elevated Ref-1/EGR1 levels increased phosphatase and PTEN levels, leading to inhibition of the Akt pathway. EGF-induced PTEN up-regulation increased apoptosis and autophagy-induced damage in A549 cells, whereas Ref-1 knockdown blocked EGF-induced PTEN up-regulation in an NOX -p22phox subunitindependent manner. In addition, p22phox knockdown restored EGF-induced eff ects, implying that changes in P2Y activity caused by EGF, which activates NOX via RAC1, infl uenced Ref-1-mediated redox regulation. Finally, EGF similarly attenuated cell proliferation and promoted autophagy and apoptosis in vivo in a xenograft model using A549 cells. Th ese fi ndings reveal that EGF-induced redox signaling is linked to Ref-1-induced death in NSCLC cells.
Ho Gun Kim
Chonnam National University, Gwangju, South Korea
Title: DNA methylation of microRNA genes in gastric carcinoma and its clinicopathological association
Biography:
Ho Gun Kim is a Professor in the Department of Surgery and Pathology at Chonnam National University Medical School, Gwangju, South Korea.
Abstract:
Background & Aim: To explore the role of epigenetic mechanisms in the down-regulation of miRNA genes, we examined the presence of DNA methylation-associated silencing of miRNAs in gastric carcinoma and observed that aberrant methylation of these miRNAs is associated with expression of target gene products. Materials & Methods: Th e extent of promoter methylation of has-miR-9-1, has-miR-9-3, has-miR-129-2 and has-miR-137 was assessed using methylation-specifi c polymerase chain reaction in 100 gastric carcinoma tissues and corresponding non-tumor tissues. Th e potential target gene products of miRNAs were studied by immunohistochemistry and the relationship between methylation profi les of miRNAs. Results: Methylation of the has-miR-9-3 and has-miR-137 CpG island was frequently observed in tumor tissues (89% and 86%, respectively) and non-tumor tissues in 100 gastric carcinoma patients (70% and 78%). However, methylation level of the has-miR-129-2 did not shown signifi cant diff erence in tumor tissues (97%) compared with non-tumor tissues (90%) and normal gastric tissues (90%). Expression of NF-κB and SOX4 protein, which are has-miR-9 and has-miR-129-2 potential target respectively, were inversely correlated with methylation level of miRNAs. Conclusion: Th e results suggest that specifi c miRNAs methylation in gastric carcinoma could be an important molecular mechanism causing loss of control of its target and it may be correlated with the high transcriptional activity of target gene. Epigenetic silencing of some miRNAs may involve in the early stage of gastric carcinogenesis.